Federica Pizzo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Federica Pizzo has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Giovanni Duro
Institute for Biomedical Research and Innovation (IRIB), National Research Council (CNR), 90146 Palermo, Italy
2 shared publications - Carmela Zizzo
Institute of Biomedicine and Molecular Immunology "A. Monroy", National Research Council, Palermo, Italy
1 shared publication - Caterina Bartolotta
Dipartimento Biomedico di Medicina Interna e Specialistica, University of Palermo, Via del Vespro 141, Palermo, Italy
1 shared publication - Christiano Argano
Internal Medicine Department iGR, National Relevance Hospital Trust, ARNAS Civico, Di Cristina e Benfratelli, 90127 Palermo, Italy
1 shared publication - Daniela Colomba
Echocardiography Laboratory, Biomedical Department of Internal Medicine and Specialities (DiBiMIS), University of Palermo, Piazza delle Cliniche, 2, 90127, Palermo, Italy,
1 shared publication - Domenico Nuzzo
Institute for Biomedical Research and Innovation, National Research Council of Italy, Palermo, Italy
1 shared publication
Latest Publications
- Open Access
- 7 January 2014
- Published by Springer Nature in BMC Research Notes
- Vol. 7 (1) , 11
De novo mutation in a male patient with Fabry disease: a case report
Fabry disease is an X-linked inherited metabolic condition where the deficit of the α-galactosidase A enzyme, encoded by the GLA gene, leads to glycosphingolipid storage, mainly globotriaosylceramide. To date, more than 600 mutations have been identified in human GLA gene that are responsible for FD, including missense and nonsense mutations, small and large deletions. Such mutations are usually inherited, and cases of de novo onset occur rarely.
- 7 January 2014
- Published by Springer Nature in BMC Research Notes
- Vol. 7 (1) , 11
Open AccessDe novo mutation in a male patient with Fabry disease: a case report
Fabry disease is an X-linked inherited metabolic condition where the deficit of the α-galactosidase A enzyme, encoded by the GLA gene, leads to glycosphingolipid storage, mainly globotriaosylceramide. To date, more than 600 mutations have been identified in human GLA gene that are responsible for FD, including missense and nonsense mutations, small and large deletions. Such mutations are usually inherited, and cases of de novo onset occur rarely.
- Open Access
- 29 May 2008
- Published by Springer Nature in Immunity & Ageing
- Vol. 5 (1) , 4
Endothelial nitric oxide synthase gene polymorphisms and cardiovascular damage in hypertensive subjects: an Italian case-control study
Background: Nitric oxide (NO) synthesized by endothelial nitric oxide synthase (eNOS) plays an important role in regulation of endothelial function and in the control of blood pressure. However, the results from some studies on the association between three clinically relevant eNOS gene polymorphisms (G894T, T786C and intron 4b/a) and essential hypertension are unclear. We designed a case-control study to evaluate the influence of eNOS polymorphisms on target organ damage in 127 hypertensives and 67 normotensives. Clinical evaluation, biochemical parameters, Urinary Albumin Excretion (UAE) and echocardiogram were performed to characterize target organ damage. eNOS polymorphism were recognized by PCR method. Results: The distribution of eNOS genotypes was similar in hypertensives and normotensives but 4aa was present in the 2.5% of hypertensives and completely absent in normotensives. Subjects with 4bb, G894T, and T786C genotypes showed an increased prevalence of target organ damage. Moreover prevalence of G894T and introne 4 variants was significantly higher in hypertensives than in normotensives both with cardiovascular damage. Logistic regression analysis didn't show any association between eNOS polymorphisms, Body Mass Index (BMI), hypertension, gender and cardiovascular damage. Only the age (OR 1.11; IC 95% 1.06–1.18) was predictive of cardiovascular damage in our population. Conclusion: Our results seem to indicate a lack of association with eNOS variants and cardiovascular damage onset.
- 29 May 2008
- Published by Springer Nature in Immunity & Ageing
- Vol. 5 (1) , 4
Open AccessEndothelial nitric oxide synthase gene polymorphisms and cardiovascular damage in hypertensive subjects: an Italian case-control study
Background: Nitric oxide (NO) synthesized by endothelial nitric oxide synthase (eNOS) plays an important role in regulation of endothelial function and in the control of blood pressure. However, the results from some studies on the association between three clinically relevant eNOS gene polymorphisms (G894T, T786C and intron 4b/a) and essential hypertension are unclear. We designed a case-control study to evaluate the influence of eNOS polymorphisms on target organ damage in 127 hypertensives and 67 normotensives. Clinical evaluation, biochemical parameters, Urinary Albumin Excretion (UAE) and echocardiogram were performed to characterize target organ damage. eNOS polymorphism were recognized by PCR method. Results: The distribution of eNOS genotypes was similar in hypertensives and normotensives but 4aa was present in the 2.5% of hypertensives and completely absent in normotensives. Subjects with 4bb, G894T, and T786C genotypes showed an increased prevalence of target organ damage. Moreover prevalence of G894T and introne 4 variants was significantly higher in hypertensives than in normotensives both with cardiovascular damage. Logistic regression analysis didn't show any association between eNOS polymorphisms, Body Mass Index (BMI), hypertension, gender and cardiovascular damage. Only the age (OR 1.11; IC 95% 1.06–1.18) was predictive of cardiovascular damage in our population. Conclusion: Our results seem to indicate a lack of association with eNOS variants and cardiovascular damage onset.